• Press Releases
  • In the News
  • Additional Partnership

January 13, 2021

Tempus Announces Companion Diagnostic Collaboration with A2 Biotherapeutics

Tempus, a leader in artificial intelligence and precision medicine, today announced a strategic collaboration to develop a companion diagnostic (CDx) test with A2 Biotherapeutics for its new therapy targeting patients with Loss of Heterozygosity (LOH). It is anticipated that this collaboration could also provide a platform for the...

January 11, 2021

Tempus Unveils A Breakthrough in AI for Oncologists: Tempus ONE

Tempus, a leader in AI-enabled diagnostics, today unveiled a breakthrough technology for oncologists, Tempus ONE. This smart, voice-enabled, portable device brings Tempus’ proprietary platform and unparalleled library of multi-modal data to life, offering physicians real-time access to all the clinical insights and data contained in Tempus’ genomic reports...

December 14, 2020

Tempus Announces Abdul Hamid Halabi as Senior Vice President of Data Products

Tempus, a leader in artificial intelligence (AI) and precision medicine, today announced that Abdul Hamid Halabi has joined as Senior Vice President of Data Products. Abdul has been a pioneer in AI and healthcare, developing key concepts in AI-powered diagnostics and intelligent medical devices and will leverage his...

December 10, 2020

Tempus Announces $200 Million Series G-2 Financing

Tempus, a leader in artificial intelligence and precision medicine, today announced an additional $200 million financing at a post-money valuation of $8.1 billion dollars, and an additional $250 million of convertible debt. The investors include Baillie Gifford, Franklin Templeton, Google, Novo Holdings, and funds and accounts managed by T. Rowe Price....

November 24, 2020

Tempus CE Marks Its Broad-Panel Genomic Sequencing Test, xT

Tempus, a leader in artificial intelligence and precision medicine, today announced that it has CE marked its signature broad-panel genomic sequencing assay, xT. The CE marked xT test is now available for clinical use in Europe. As part of Tempus’ broader regulatory strategy, European clinicians and their patients wil...

November 16, 2020

Tempus and Yale Announce Research Collaboration to Accelerate COVID-19 Test Development

Tempus, a leader in artificial intelligence and precision medicine, and the Yale School of Public Health announced a research collaboration to accelerate the development of COVID-19 diagnostic tests in the U.S. This partnership will leverage SalivaDirectTM, a saliva-based laboratory diagnostic test that has been developed by researchers...

November 12, 2020

Tempus Announces Glioblastoma Data Offering in Collaboration with ASCO

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announced that in collaboration with the American Society of Clinical Oncology (ASCO), the academic research community now has access to a dataset of 500 Glioblastoma patients with matched molecular and clinically data....

November 2, 2020

Tempus Announces Strategic Collaboration with Janssen Applying Data Science to Enhance Therapeutic Development

Tempus, a leader in artificial intelligence (AI) and precision medicine, today announced a strategic collaboration with Janssen Research & Development, LLC (Janssen), in which Tempus will work closely with Janssen data scientists and oncologists focused on oncology clinical development programs. The collaboration is part of a multi-year data agreem...

September 16, 2020

Tempus and LabCorp Announce Collaboration to Accelerate Clinical Trial Patient Participation

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, and LabCorp (NYSE: LH), a leading global life sciences company, today announced a collaboration with LabCorp’s drug development business, Covance. LabCorp will participate in Tempus’s TIME Trial® Network and the comp...

June 22, 2020

Tempus Announces Christopher Mason, PhD, Joins as Vice President of Emerging Genome Technology

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announced that Christopher Mason, PhD, has joined as the Vice President of Emerging Genome Technology. Dr. Mason has been a pioneer in next-generation sequencing (NGS) diagnostics, multi-omic approaches to modeling disease,...

Show More